Drug intelligence / Profile preview

D[KLAKLAK]2-CGKRK-PEG-NW

Development stage: Preclinical
Lead developer: Sanford Burnham Prebys
Modality: Nanoparticles → Drug Delivery Systems, Peptides
Administration: Intravenous

Overview

**D[KLAKLAK]2-CGKRK-PEG-NW** is an experimental, intravenously administered iron-oxide nanoworm therapeutic developed for glioblastoma. It consists of PEG-coated iron-oxide nanoworms bearing a chimeric peptide comprising the tumor-vascular-homing peptide CGKRK and the mitochondria-disrupting pro-apoptotic peptide D[KLAKLAK]2. In mouse glioma models, the construct accumulated in glioma blood vessels, inhibited tumor growth, and significantly prolonged survival versus control treatment. It remained a preclinical research-stage nanotherapeutic with no identified marketed product or clinical development program.

Other names: D[KLAKLAK]2-CGKRK-PEG-NW

Targets

IMM (Mitochondrial inner membrane)C1QBP (Globular C1q receptor)

Beyond the preview

Go deeper on D[KLAKLAK]2-CGKRK-PEG-NW.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D[KLAKLAK]2-CGKRK-PEG-NW.

Explore the full profile